Medinex's (Catalist:OTX) stock is up by 9.1% over the past three months. However, the company's financials look a bit inconsistent and market outcomes are ultimately driven by long-term fundamentals, ...

BEDFORD, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, announced ...

Angela Kinsey and Josh Snyder join TODAY to share their recipes for lasagna roll-ups and banana bread crumb muffins from their new cookbook, “You Can Make This.” An NFL kicker just hit a 68-yard field ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...

Bristol Myers Squibb has agreed to buy privately held biotechnology company Orbital Therapeutics for $1.5 billion in cash in a deal that bolsters the drugmaker's cell-therapy portfolio. Bristol Myers ...

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...